Working… Menu

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00185120
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : January 18, 2012
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

Brief Summary:
A comparison of 2 different combinations of high blood pressure medications to treat hypertension

Condition or disease Intervention/treatment Phase
Hypertension Drug: Olmesartan medoxomil Drug: Hydroclorothiazide Drug: Benazepril Drug: Amlodipine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension
Study Start Date : September 2005
Actual Primary Completion Date : September 2006
Actual Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium

Primary Outcome Measures :
  1. Change in systolic blood pressure from the start of the study

Secondary Outcome Measures :
  1. Change in diastolic blood pressure from the start of the study
  2. Percent of patients who achieve target blood pressure goals

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Greater than 18 years of age
  • Patients with high blood pressure

Exclusion Criteria:

  • Hypertensive encephalopathy, stroke or transient ischemic attack within the past 6 months
  • History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months
  • Type 1 diabetes mellitus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00185120

Layout table for location information
United States, Alabama
Mobile, Alabama, United States, 36693
United States, California
Memorial Research Medical Center
Long Beach, California, United States, 90806
National Research Institute
Los Angeles, California, United States, 90057
Clinical Trials Research
Roseville, California, United States, 95661
Apex Research Institute
Santa Ana, California, United States, 92705
Orange County Research Center
Tustin, California, United States, 92780
Westlake Medical Center
Westlake Village, California, United States, 91361
United States, Florida
Clinical Research of South Florida
Coral Gables, Florida, United States, 33134
The Greater Fort Lauderdale Heart Group Research
Fort lauderdale, Florida, United States, 33308
SFBC International
Miami, Florida, United States, 33142
Tamarac, Florida, United States, 33321
United States, Indiana
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States, 46260
United States, Kansas
Heartland Research Associates
Wichita, Kansas, United States, 67207
United States, Maine
Androscoggin Cardiology Research
Auburn, Maine, United States, 04210
United States, North Carolina
Internal Medicine Associates of Charlotte
Charlotte, North Carolina, United States, 28211
Piedmont Medical Research Associates
Winston-salem, North Carolina, United States, 27103
United States, Ohio
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States, 45319
United States, Rhode Island
Omega Medical Research
Warwick, Rhode Island, United States, 02886
United States, Tennessee
Volunteer Research Group, University of Tennessee Med. Ctr.
Knoxville,, Tennessee, United States, 37920
United States, Texas
Punzi Medical Center
Carrollton, Texas, United States, 75006
Sponsors and Collaborators
Daiichi Sankyo, Inc.

Layout table for additonal information
Responsible Party: Daiichi Sankyo, Inc. Identifier: NCT00185120     History of Changes
Other Study ID Numbers: 866-447
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: January 18, 2012
Last Verified: January 2012
Keywords provided by Daiichi Sankyo, Inc.:
angiotensin receptor blocker
calcium channel blocker
angiotensin converting enzyme inhibitor hydroclorothiazide
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Calcium, Dietary
Olmesartan Medoxomil
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Antihypertensive Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Natriuretic Agents
Sodium Chloride Symporter Inhibitors
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Protease Inhibitors
Enzyme Inhibitors